sugammadex (Bridion)

Following a full submission

sugammadex (Bridion) is accepted for restricted use within NHS Scotland for the immediate reversal of rocuronium-induced neuromuscular blockade.

Sugammadex, when administered after rocuronium or vecuronium, has been shown to provide more rapid reversal of neuromuscular blockade than an anticholinesterase comparator and, when administered with rocuronium in the rapid sequence induction setting, gave a faster mean recovery time than using a depolarising neuromuscular blocking comparator.

Sugammadex is accepted for restricted use in the immediate reversal of rocuronium-induced neuromuscular blockade in adults only.

Sugammadex is not recommended for the routine reversal of neuromuscular blockade induced by rocuronium or vecuronium in adults, children and adolescents as the manufacturer did not present a sufficiently robust economic case to gain acceptance by SMC